Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 5 million deaths worldwide. Pneumonia and systemic inflammation contribute to its high mortality. Many viruses use heparan sulfate proteoglycans as coreceptors fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Jingyu, Lu, Mijia, Shi, Min, Cheng, Xiaogang, Kwakwa, Kristin A., Davis, Jennifer L., Su, Xinming, Bakewell, Suzanne J., Zhang, Yuexiu, Fontana, Francesca, Xu, Yalin, Veis, Deborah J., DiPersio, John F., Ratner, Lee, Sanderson, Ralph D., Noseda, Alessandro, Mollah, Shamim, Li, Jianrong, Weilbaecher, Katherine N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Pathogenesis and Immunity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006938/
https://www.ncbi.nlm.nih.gov/pubmed/35319225
http://dx.doi.org/10.1128/jvi.00057-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006938/
https://www.ncbi.nlm.nih.gov/pubmed/35319225
http://dx.doi.org/10.1128/jvi.00057-22

Ejemplares similares